| 前收盘价格 | 11.17 |
| 收盘价格 | 8.74 |
| 成交量 | 16,683,307 |
| 平均成交量 (3个月) | 2,781,311 |
| 市值 | 603,918,080 |
| 市盈率 (P/E TTM) | 3.47 |
| 预期市盈率 (P/E Forward) | 4.03 |
| 价格/销量 (P/S) | 3.76 |
| 股市价格/股市净资产 (P/B) | 2.35 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2025 |
| 营业毛利率 | 20.81% |
| 营业利益率 (TTM) | 51.49% |
| 稀释每股收益 (EPS TTM) | 0.250 |
| 总债务/股东权益 (D/E MRQ) | 0.41% |
| 流动比率 (MRQ) | 4.21 |
| 营业现金流 (OCF TTM) | -13.57 M |
| 杠杆自由现金流 (LFCF TTM) | -21.07 M |
| 资产报酬率 (ROA TTM) | 8.31% |
| 股东权益报酬率 (ROE TTM) | 19.87% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | CorMedix Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -3.5 |
| 平均 | 0.25 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.08% |
| 机构持股比例 | 34.20% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Oberweis Asset Management Inc/ | 30 Sep 2025 | 785,700 |
| Jump Financial, Llc | 30 Sep 2025 | 774,083 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 22.00 (RBC Capital, 187.02%) | 购买 |
| 中 | 16.50 (115.26%) | |
| 低 | 14.00 (D. Boral Capital, 82.65%) | 购买 |
| 平均值 | 17.25 (125.05%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 9.55 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 08 Jan 2026 | 14.00 (82.65%) | 购买 | 7.67 |
| 18 Dec 2025 | 14.00 (82.65%) | 购买 | 11.92 | |
| Needham | 08 Jan 2026 | 15.00 (95.69%) | 购买 | 7.67 |
| 12 Nov 2025 | 16.00 (108.74%) | 购买 | 11.42 | |
| HC Wainwright & Co. | 13 Nov 2025 | 18.00 (134.83%) | 购买 | 11.21 |
| RBC Capital | 21 Oct 2025 | 22.00 (187.02%) | 购买 | 11.65 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合